• español
  • English
  • français
  • Deutsch
  • português (Brasil)
  • italiano
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Ricerca

    Tutto UVaDOCArchiviData di pubblicazioneAutoriSoggettiTitoli

    My Account

    Login

    Estadísticas

    Ver Estadísticas de uso

    Compartir

    Mostra Item 
    •   UVaDOC Home
    • PRODUZIONE SCIENTIFICA
    • Grupos de Investigación
    • Grupo de Materiales Avanzados y Nanobiotecnología (BIOFORGE)
    • BIOFORGE - Artículos de revista
    • Mostra Item
    •   UVaDOC Home
    • PRODUZIONE SCIENTIFICA
    • Grupos de Investigación
    • Grupo de Materiales Avanzados y Nanobiotecnología (BIOFORGE)
    • BIOFORGE - Artículos de revista
    • Mostra Item
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano

    Exportar

    RISMendeleyRefworksZotero
    • edm
    • marc
    • xoai
    • qdc
    • ore
    • ese
    • dim
    • uketd_dc
    • oai_dc
    • etdms
    • rdf
    • mods
    • mets
    • didl
    • premis

    Citas

    Por favor, use este identificador para citar o enlazar este ítem:https://uvadoc.uva.es/handle/10324/51954

    Título
    The Incorporation of etanercept into a porous tri-layer scaffold for restoring and repairing cartilage tissue
    Autor
    Campos, Yaima
    Fuentes, Gastón
    Almirall, Amisel
    Que, Ivo
    Schomann, Timo
    Chung, Chih Kit
    Jorquera Cordero, Carla
    Quintanilla Sierra, LuisAutoridad UVA
    Rodríguez Cabello, José CarlosAutoridad UVA Orcid
    Chan, Alan
    Cruz, Luis
    Año del Documento
    2022
    Editorial
    MDPI
    Descripción
    Producción Científica
    Documento Fuente
    Pharmaceutics, 2022, vol. 14, n. 2, 282
    Abstract
    Cartilage diseases currently affect a high percentage of the world’s population. Almost all of these diseases, such as osteoarthritis (OA), cause inflammation of this soft tissue. However, this could be controlled with biomaterials that act as an anti-inflammatory delivery system, capable of dosing these drugs over time in a specific area. The objective of this study was to incorporate etanercept (ETA) into porous three-layer scaffolds to decrease the inflammatory process in this soft tissue. ETA is a blocker of pro-inflammatory cytokines, such as tumour necrosis factor alpha (TNF-α) and interleukin 6 (IL-6). For this reason, the scaffold was built based on natural polymers, including chitosan and type I collagen. The scaffold was grafted next to subchondral bone using hydroxyapatite as filler. One of the biomaterials obtained was also crosslinked to compare its mechanical properties with the non-treated one. Both samples’ physicochemical properties were studied with SEM, microCT and photoacoustic imaging, and their rheological properties were also compared. The cell viability and proliferation of the human chondrocyte C28/I2 cell line were studied in vitro. An in vitro and in vivo controlled release study was evaluated in both specimens. The ETA anti-inflammatory effect was also studied by in vitro TNF-α and IL-6 production. The crosslinked and non-treated scaffolds had rheological properties suitable for this application. They were non-cytotoxic and favoured the in vitro growth of chondrocytes. The in vitro and in vivo ETA release showed desirable results for a drug delivery system. The TNF-α and IL-6 production assay showed that this drug was effective as an anti-inflammatory agent. In an in vivo OA mice model, safranin-O and fast green staining was carried out. The OA cartilage tissue improved when the scaffold with ETA was grafted in the damaged area. These results demonstrate that this type of biomaterial has high potential for clinical applications in tissue engineering and as a controlled drug delivery system in OA articular cartilage.
    Palabras Clave
    Osteoarthritis
    Osteoartritis
    Tissue engineering
    Ingeniería de tejidos
    Etanercept
    Cartilage - Implants
    Cartílago - Implantes
    ISSN
    1999-4923
    Revisión por pares
    SI
    DOI
    10.3390/pharmaceutics14020282
    Patrocinador
    European Union through the Erasmus PLUS doctoral fellowship (project 2015-1-NL01-KA 107-008639)
    VIDI personal grant (project 723.012.110)
    Patrocinador
    info:eu-repo/grantAgreement/EC/H2020/644373
    info:eu-repo/grantAgreement/EC/H2020/777682
    info:eu-repo/grantAgreement/EC/H2020/807281
    info:eu-repo/grantAgreement/EC/H2020/852985
    info:eu-repo/grantAgreement/EC/H2020/734684
    info:eu-repo/grantAgreement/EC/H2020/955335
    info:eu-repo/grantAgreement/EC/H2020/952520
    info:eu-repo/grantAgreement/EC/H2020/872391
    info:eu-repo/grantAgreement/EC/H2020/860173
    info:eu-repo/grantAgreement/EC/H2020/675743
    info:eu-repo/grantAgreement/EC/H2020/861190
    info:eu-repo/grantAgreement/EC/H2020/857894
    info:eu-repo/grantAgreement/EC/H2020/859908
    info:eu-repo/grantAgreement/EC/H2020/872860
    Version del Editor
    https://www.mdpi.com/1999-4923/14/2/282
    Propietario de los Derechos
    © 2022 The Authors
    Idioma
    eng
    URI
    https://uvadoc.uva.es/handle/10324/51954
    Tipo de versión
    info:eu-repo/semantics/publishedVersion
    Derechos
    openAccess
    Aparece en las colecciones
    • BIOFORGE - Artículos de revista [89]
    Mostra tutti i dati dell'item
    Files in questo item
    Nombre:
    Incorporation-Etanercept.pdf
    Tamaño:
    10.60Mb
    Formato:
    Adobe PDF
    Thumbnail
    Mostra/Apri
    Attribution-NonCommercial-NoDerivatives 4.0 InternacionalLa licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional

    Universidad de Valladolid

    Powered by MIT's. DSpace software, Version 5.10